Online inquiry

IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11657MR)

This product GTTS-WQ11657MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11657MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2071MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ5813MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ3035MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ4107MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ10985MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ12906MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ13714MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ2778MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW